Indoco Remedies Ltd's CRO arm AnaCipher updates on USFDA inspection

Indoco Remedies Limited's Clinical Research Organisation, AnaCipher, located in Hyderabad, was inspected by the United States Food and Drug Administration (USFDA) in July 2022.

The USFDA has confirmed that no objectionable conditions were observed during their remote assessment.

Commenting on this positive development, Ms. Aditi Panandikar, Managing Director, Indoco Remedies Limited, said that "This clearance by USFDA is in continuation to seventh successive FDA inspections which concluded with ZERO 483s for AnaCipher CRO. We are committed to strict adherence to all applicable guidelines and regulations and maintaining the highest quality standards in delivering quality services to our clients."

Shares of Indoco Remedies Limited was last trading in BSE at Rs. 352.85 as compared to the previous close of Rs. 344.25. The total number of shares traded during the day was 1413 in over 171 trades.

The stock hit an intraday high of Rs. 354.00 and intraday low of 340.05. The net turnover during the day was Rs. 489442.00.

Source : Equity Bulls

Keywords

IndocoRemedies INE873D01024 ClinicalResearchOrganisaton AnaCipher Inspection USFDA